TABLE 2.
Estimated required sample sizes relative to using TMS as the outcome in a 3‐year trial
| Outcome | ENROLL‐HD | COHORT | TRACK‐HD | PREDICT‐HD | PHAROS |
|---|---|---|---|---|---|
| TMS | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| TFC | 1.43 | 2.33 | 123 | 3.35 | 21.43 |
| SDMT | 6.51 | 32.3 | 3.94 | 1.29 | 2.29 |
| Stroop‐W | a | 90.7 | 5.54 | 1.75 | – |
| Stroop‐C | 82.6 | a | – | 1.66 | – |
| Stroop‐I | a | 730 | – | 2.26 | – |
| Verbal‐C | a | – | – | – | – |
| Verbal‐L | a | a | – | – | – |
| Trail‐A | 37.2 | – | – | 2.74 | – |
| Trail‐B | 56.5 | – | – | 2.18 | – |
–, not assessed in Table 1.
Negative effect sizes in Table 1, therefore no sample size estimable.
COHORT, Cooperative Huntington's Observational Research Trial; PREDICT‐HD, Neurobiological Predictors of Huntington's Disease; PHAROS, Prospective Huntington at Risk Observational Study; TMS, total motor score; TFC, total functional capacity; SDMT, Symbol Digit Modalities Test; Stroop‐W, Stroop Color and Word Test (word condition); Stroop‐C, Stroop Color and Word Test (color condition); Stroop‐I, Stroop Color and Word Test (interference condition); Verbal‐C, categorical verbal fluency test; Verbal‐L, letter verbal fluency test; Trail‐A, Trail Making Test Part A; Trail‐B, Trail Making Test Part B.